Join
Live feed
·
PRReleasevia Quantisnow
Fulcrum Therapeutics Inc. logo

Fulcrum Therapeutics Announces Positive 12-Week Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease

ByQuantisnow·Wall Street's wire, on your screen.
FULC· Fulcrum Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track FULC (Fulcrum Therapeutics Inc.) and more on Quantisnow.